Odyssey Thera has been awarded US Patent 7,488,583, "Fragment complementation assays for G-protein-coupled receptors and their signaling pathways."
Inventors listed on the patent are John Westwick, Brigitte Keon, and Marnie MacDonald.
According to its abstract, the patent provides a method of screening a candidate drug, a compound library or a biological extract to identify activators or inhibitors of G-protein-coupled receptors or G-protein-coupled pathways, comprising the use of a fluorescent protein fragment complementation assay to construct an assay for one or more steps in a G-protein-coupled pathway; testing the effects of the candidate drugs, compound library, or biological extract on the receptor or pathway of interest; and using the results of the screening to identify specific agents that activate or inhibit the receptor or pathway of interest. The patent also provides a method for identifying a drug lead that modulates the activity of a G-protein-coupled pathway using a fluorescent protein fragment complementation assay. The method described in the patent is used to identify agonists, antagonists, activators, or inhibitors of G-protein coupled receptors or G-protein-coupled pathways.
(see related story this issue)
The University of Pennsylvania and the Carnegie Institute of Washington have been awarded US Patent 7,488,467, "High-throughput genetic screening of lipid and cholesterol processing using fluorescent compounds."
The inventors listed on the patent are Steven Farber, Michael Pack, and Marnie Halpern.
The patent describes a method using fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to enable researchers to screen zebrafish for phenotypes representing perturbations of lipid processing; genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and compounds designed to treat disorders of phospholipid and/or cholesterol metabolism, according to its abstract.